Trial · NCT04437511
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population) | Baseline, Week 76 | All randomized participants with a baseline and at least one postbaseline iADRS data point. | score on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population) | Baseline, Week 76 | All randomized participants with baseline Intermediate Tau level and with baseline and at least one postbaseline iADRS data point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline on the Mini Mental State Examination (MMSE) Score (Overall Population) | Baseline, Week 76 | All randomized participants with a baseline and at least one postbaseline MMSE data point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline on the Mini Mental State Examination (MMSE) Score (Intermediate (Low-medium) Tau Population) | Baseline, Week 76 | All randomized participants with baseline Intermediate Tau level and with baseline and at least one postbaseline MMSE data point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Overall Population) | Baseline, Week 76 | All randomized participants with a baseline and at least one postbaseline ADAS-Cog13 data point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Intermediate (Low-medium) Tau Population) | Baseline, Week 76 | All randomized participants with baseline Intermediate Tau level and with baseline and at least one postbaseline ADAS-Cog13 data point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Overall Population) | Baseline, Week 76 | All randomized participants with a baseline and at least one postbaseline CDR-SB data point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Intermediate (Low-medium) Tau Population) | Baseline, Week 76 | All randomized participants with baseline Intermediate Tau level and with baseline and at least one postbaseline CDR-SB data point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) Score (Overall Population) | Baseline, Week 76 | All randomized participants with a baseline and at least one postbaseline ADCS-iADL data point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) Score (Intermediate (Low-medium) Tau Population) | Baseline, Week 76 | All randomized participants with a baseline Intermediate Tau level and with baseline and at least one postbaseline ADCS-iADL data point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Brain Amyloid Plaque Deposition as Measured by Amyloid Positron Emission Tomography (PET) Scan | Baseline, Week 76 | All randomized participants with a baseline and at least one postbaseline amyloid PET scan data point. | centiloids | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Brain Tau Deposition as Measured by Flortaucipir F18 PET Scan | Baseline, Week 76 | All randomized participants with a baseline and post-baseline tau PET scan. | standardized uptake value ratio (SUVR) | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Brain Volume as Measured by Volumetric Magnetic Resonance Imaging (vMRI) | Baseline, Week 76 | All randomized participants with a baseline and at least one postbaseline vMRI data point. | cubic centimeter (cm^3) | LEAST_SQUARES_MEAN |
| SECONDARY | Pharmacokinetics (PK): Average Serum Concentration at Steady State of Donanemab | Week 16 to week 20 | All randomized participants who received at least one dose of study drug and had evaluable PK data. | micrograms per milliliter (μg/mL) | GEOMETRIC_MEAN |
| SECONDARY | Number or Participants With Anti-Donanemab Antibodies | Baseline through Week 76 | All randomized participants who received at least one dose of study drug and had evaluable anti-drug antibody measurement. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04437511/outcomes